Illumina Inc. (Nasdaq: ILMN), a genomics and molecular diagnostics company headquartered in San Diego, closed in late January on its acquisition of Boulder-based biotech firm SomaLogic Inc.
Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights Expands commercial reach with substantial cross-selling ...
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter ...
SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human ...
Hosted on MSN
Standard BioTools outlines $165M-$175M revenue target for FY2025 while driving proteomics partnerships
CEO Michael Egholm highlighted that Standard BioTools delivered Q1 2025 revenues of $40.8 million, aligned with their plan despite a challenging operating backdrop. He emphasized improvements in ...
BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, ...
SomaLogic Inc.’s SLGC stock was up about 12% in premarket trades on Wednesday after the Boulder, Colo.-based specialist in cell proteins agreed to be acquired in an all-stock merger with Standard ...
Standard BioTools, is engaged in product rationalization, cost-cutting and operational efficiency measures in an attempt to turn its business around and transition to profitability. The company’s ...
The Dow Jones index closed higher by around 0.2% on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders ...
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today ...
Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results